Global Pneumococcal Vaccine Polyvalent Market Size By Type (Prevnar 13, Pneumovax23), By Application (18 years and younger, 19 to 64 years old), By Region, And Segment Forecasts, 2023 to 2032

The Global Pneumococcal Vaccine Polyvalent Market was valued at USD 9.1 billion in 2023 and is projected to reach USD 15.7 billion by 2031, growing at a CAGR of 6.8% during the forecast period (2023–2031). Market expansion is driven by the increasing global prevalence of pneumococcal diseases, government immunization programs, growing awareness about vaccination benefits, and technological advancements in vaccine development. Polyvalent vaccines, which target multiple serotypes of Streptococcus pneumoniae, are becoming a cornerstone in preventing invasive pneumococcal diseases, especially in children, the elderly, and immunocompromised populations.

Drivers:

1. Growing Immunization Coverage Worldwide

The rise in national immunization programs and inclusion of pneumococcal conjugate vaccines (PCVs) in routine schedules across countries is significantly boosting market growth.

2. Rising Incidence of Pneumococcal Infections

Higher disease burden in both developed and developing countries, particularly among the pediatric and geriatric population, is elevating demand for broader-spectrum vaccines.

3. Advancements in Vaccine Technology

Ongoing R&D in conjugate and protein-based vaccine formulations enables longer-lasting immunity and better protection against more pneumococcal strains.

Restraints:

1. High Cost of Vaccines

The relatively high price of polyvalent pneumococcal vaccines poses challenges, particularly for middle- and low-income countries with constrained healthcare budgets.

2. Limited Awareness in Developing Regions

In several emerging economies, lack of awareness about pneumococcal disease severity and preventive vaccines restricts market penetration.

Opportunity:

1. Expanding Geriatric Population

As the global elderly population grows, so does the demand for vaccines that provide broad protection against pneumonia and other pneumococcal infections.

2. Integration with Global Health Initiatives

Collaborations with global organizations like GAVI and WHO to increase vaccine accessibility in underserved regions open new avenues for manufacturers.

Market by System Type Insights:

The 13-valent pneumococcal conjugate vaccine (PCV13) segment held the dominant share in 2023 due to its wide serotype coverage and global recommendation by healthcare agencies. However, the 20-valent PCV segment is expected to witness the fastest growth owing to its enhanced protective efficacy against additional serotypes, making it a preferred choice in adult immunization programs.

Market by End-use Insights:

In 2023, the Pediatric Segment accounted for the largest revenue share due to routine immunization in infants and young children. Meanwhile, the Geriatric Segment is poised to grow rapidly during the forecast period as awareness of adult pneumococcal vaccination improves and healthcare systems promote preventive care for aging populations.

Market by Regional Insights:

North America dominated the global market in 2023, driven by high vaccination rates, supportive reimbursement policies, and the presence of leading vaccine manufacturers. However, Asia-Pacific is anticipated to record the highest CAGR from 2023 to 2031, attributed to increasing healthcare investments, public health initiatives, and growing population base.

Competitive Scenario:

Key players in the Global Pneumococcal Vaccine Polyvalent Market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., and SK Bioscience Co., Ltd. These companies are actively involved in expanding their vaccine portfolios, securing regulatory approvals, and partnering with government agencies to increase global vaccine access.

Scope of Work – Global Pneumococcal Vaccine Polyvalent Market

Key Market Developments:

February 2023: Pfizer received FDA approval for its 20-valent pneumococcal conjugate vaccine for adult use, enhancing its competitiveness against traditional PCVs.

July 2023: Merck launched its updated adult PCV formulation in Europe targeting expanded serotype coverage.

March 2024: The Serum Institute of India partnered with GAVI to supply low-cost PCV formulations to African and Southeast Asian nations.

FAQs:

1) What is the current market size of the Global Pneumococcal Vaccine Polyvalent Market?

The market was valued at USD 9.1 billion in 2023.

2) What is the major growth driver of the Global Pneumococcal Vaccine Polyvalent Market?

Major drivers include expanding immunization coverage and the rising burden of pneumococcal infections.

3) Which is the largest region during the forecast period in the Global Pneumococcal Vaccine Polyvalent Market?

North America holds the largest market share due to advanced healthcare infrastructure and high awareness.

4) Which segment accounted for the largest market share in Global Pneumococcal Vaccine Polyvalent Market?

The Pediatric segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pneumococcal Vaccine Polyvalent Market?

Key players include Pfizer, GlaxoSmithKline, Merck, Sanofi, Serum Institute of India, Walvax Biotechnology, and SK Bioscience.